Condition: Advanced Solid Tumor · HR+/HER2- Breast Cancer · HR+, HER2-, Advanced Breast Cancer · Sponsor: Avenzo Therapeutics, Inc.
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
This description comes directly from the study's public registry record.
Medical Information · (858) 239-2944 · ClinicalTrials@avenzotx.com
Always discuss trial participation with your own doctor first.
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
| NYU Langone Medical Center (Tisch Hospital) | New York, New York, United States | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| Oklahoma University | Oklahoma City, Oklahoma, United States | Recruiting |
| Providence Cancer Institute | Portland, Oregon, United States | Recruiting |
| Sidney Kimmel Cancer Center (SKCC) at Jefferson Health | Philadelphia, Pennsylvania, United States | Recruiting |
| Texas Oncology - DFW | Dallas, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| Macquarie University Hospital | Macquarie University, New South Wales, Australia | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05867251